Literature DB >> 11693196

Effects of losartan on the collagen degradative enzymes in hypertrophic and congestive types of cardiomyopathic hamsters.

K Masutomo1, N Makino, M S Fushiki.   

Abstract

The present study was undertaken to determine the effects of AT1 receptor blockade which occurred in response to losartan, on the extracellular matrix (ECM) degradation process in the Bio 14.6 (n = 12) and Bio 53.58 (n = 12) strains which are referred as models of hypertrophic and dilated cardiomyopathy, respectively. The administration of losartan (30 mg/kg/day) in hamsters from 10-20 weeks of age reduced the accumulation of the left ventricular collagen matrix in both of the Bio 14.6 and the Bio 53.58 strains. According to the RT-PCR, the levels of mRNA for matrix metalloproteinase (MMP) and the tissue inhibitor of MMP (TIMP) were examined. MMP-1, -2, -3, and -9 were more enhanced in both myopathic strains than in the control F1beta, strains. With losartan, the levels of MMP-1, -2, -9, TIMP-1 and -2 decreased in the both strains but those for MMP-3 did not in Bio 14.6 strains. TIMP-3 and -4 mRNA levels did not change in any of the experimental hamsters, whether treated or untreated with losartan. The Western blots also showed similar observations in the both strains as seen in mRNA expressions although MMP-2 in the Bio 53.58 strains did not differ between treated and untreated with losartan. Although losartan has an inhibitory effect on collagen accumulation in the development of cardiomyopathy, MMPs (-1, -2, -9) and TIMPs (-1, -2) seem to be susceptible to responding to losartan in Bio cardiomyopathic hamsters.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11693196     DOI: 10.1023/a:1011942824139

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  29 in total

1.  Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis.

Authors:  A H Baker; A B Zaltsman; S J George; A C Newby
Journal:  J Clin Invest       Date:  1998-03-15       Impact factor: 14.808

2.  Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy.

Authors:  C V Thomas; M L Coker; J L Zellner; J R Handy; A J Crumbley; F G Spinale
Journal:  Circulation       Date:  1998-05-05       Impact factor: 29.690

Review 3.  Matrix metalloproteinases and cardiovascular disease.

Authors:  C M Dollery; J R McEwan; A M Henney
Journal:  Circ Res       Date:  1995-11       Impact factor: 17.367

4.  Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice.

Authors:  L E Rohde; A Ducharme; L H Arroyo; M Aikawa; G H Sukhova; A Lopez-Anaya; K F McClure; P G Mitchell; P Libby; R T Lee
Journal:  Circulation       Date:  1999-06-15       Impact factor: 29.690

5.  Cardiac collagen remodeling in the cardiomyopathic Syrian hamster and the effect of losartan.

Authors:  I M Dixon; H Ju; N L Reid; T Scammell-La Fleur; J P Werner; G Jasmin
Journal:  J Mol Cell Cardiol       Date:  1997-07       Impact factor: 5.000

6.  Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters.

Authors:  Y Taniyama; R Morishita; H Nakagami; A Moriguchi; H Sakonjo; K Matsumoto; T Nakamura; J Higaki; T Ogihara
Journal:  Circulation       Date:  2000-07-11       Impact factor: 29.690

7.  Differential expression of tissue inhibitors of metalloproteinases in the failing human heart.

Authors:  Y Y Li; A M Feldman; Y Sun; C F McTiernan
Journal:  Circulation       Date:  1998-10-27       Impact factor: 29.690

8.  Effects of quinapril, a new angiotensin converting enzyme inhibitor, on left ventricular failure and survival in the cardiomyopathic hamster. Hemodynamic, morphological, and biochemical correlates.

Authors:  S J Haleen; R E Weishaar; R W Overhiser; R F Bousley; J A Keiser; S R Rapundalo; D G Taylor
Journal:  Circ Res       Date:  1991-05       Impact factor: 17.367

9.  Chronic administration of angiotensin II receptor antagonist, TCV-116, in cardiomyopathic hamsters.

Authors:  F Nakamura; M Nagano; R Kobayashi; J Higaki; H Mikami; N Kawaguchi; S Onishi; T Ogihara
Journal:  Am J Physiol       Date:  1994-12

Review 10.  Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system.

Authors:  K T Weber; C G Brilla
Journal:  Circulation       Date:  1991-06       Impact factor: 29.690

View more
  4 in total

Review 1.  Matrix metalloproteinases: pathways of induction by bioactive molecules.

Authors:  Toshihiro Tsuruda; Lisa C Costello-Boerrigter; John C Burnett
Journal:  Heart Fail Rev       Date:  2004-01       Impact factor: 4.214

Review 2.  Extracellular matrix molecules: potential targets in pharmacotherapy.

Authors:  Hannu Järveläinen; Annele Sainio; Markku Koulu; Thomas N Wight; Risto Penttinen
Journal:  Pharmacol Rev       Date:  2009-06       Impact factor: 25.468

Review 3.  Regeneration in heart disease-Is ECM the key?

Authors:  Ahmad F Bayomy; Michael Bauer; Yiling Qiu; Ronglih Liao
Journal:  Life Sci       Date:  2012-09-12       Impact factor: 5.037

Review 4.  Effects of Renin-Angiotensin-Aldosterone System Inhibition on Left Ventricular Hypertrophy, Diastolic Function, and Functional Status in Patients With Hypertrophic Cardiomyopathy: A Systematic Review.

Authors:  Hamza Akhtar; Hussein Al Sudani; Muhammad Hussein; Mehr Un Nisa Farhan; Karim Elkholy
Journal:  Cureus       Date:  2022-07-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.